Casdin Capital is an investment fund managing more than $1.01 trillion ran by Steve Giordano. There are currently 36 companies in Mr. Giordano’s portfolio. The largest investments include Revolution Medicines Inc and Biolife Solutions Inc, together worth $305 billion.
As of 7th February 2024, Casdin Capital’s top holding is 5,714,775 shares of Revolution Medicines Inc currently worth over $164 billion and making up 16.2% of the portfolio value.
Relative to the number of outstanding shares of Revolution Medicines Inc, Casdin Capital owns more than approximately 0.1% of the company.
In addition, the fund holds 8,707,165 shares of Biolife Solutions Inc worth $141 billion, whose value grew 38.9% in the past six months.
The third-largest holding is Sarepta Therapeutics Inc worth $97.1 billion and the next is Relay Therapeutics worth $81.3 billion, with 7,387,943 shares owned.
Currently, Casdin Capital's portfolio is worth at least $1.01 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Casdin Capital office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Steve Giordano serves as the General Counsel at Casdin Capital.
In the most recent 13F filing, Casdin Capital revealed that it had opened a new position in
Neurogene Inc and bought 524,616 shares worth $10.2 billion.
The investment fund also strengthened its position in Revolution Medicines Inc by buying
3,904,775 additional shares.
This makes their stake in Revolution Medicines Inc total 5,714,775 shares worth $164 billion.
Revolution Medicines Inc soared 13.8% in the past year.
On the other hand, there are companies that Casdin Capital is getting rid of from its portfolio.
Casdin Capital closed its position in Eqrx Inc on 14th February 2024.
It sold the previously owned 39,527,669 shares for $73.5 billion.
Steve Giordano also disclosed a decreased stake in Sarepta Therapeutics Inc by approximately 0.1%.
This leaves the value of the investment at $97.1 billion and 1,006,500 shares.
The two most similar investment funds to Casdin Capital are Onex Canada Asset Management and Bramshill Investments. They manage $1.01 trillion and $1.02 trillion respectively.
Casdin Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 77.4% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
8% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $5.64 billion.
These positions were updated on February 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Revolution Medicines Inc |
215.73%
5,714,775
|
$163,899,747,000 | 16.16% |
| Biolife Solutions Inc |
12.76%
8,707,165
|
$141,491,431,000 | 13.95% |
| Sarepta Therapeutics Inc |
0.84%
1,006,500
|
$97,056,795,000 | 9.57% |
| Relay Therapeutics, Inc. |
23.16%
7,387,943
|
$81,341,252,000 | 8.02% |
| Eqrx Inc |
Closed
39,527,669
|
$73,521,464,000 | |
| Structure Therapeutics Inc |
9.51%
1,091,867
|
$44,504,499,000 | 4.39% |
| Intellia Therapeutics Inc |
13.73%
1,450,000
|
$44,210,500,000 | 4.36% |
| Illumina Inc |
101.94%
313,000
|
$43,582,120,000 | 4.30% |
| Verve Therapeutics Inc |
27.47%
3,009,094
|
$41,946,770,000 | 4.14% |
| Alnylam Pharmaceuticals Inc |
30.36%
195,000
|
$37,324,950,000 | 3.68% |
| Somalogic Inc |
No change
12,604,275
|
$31,888,816,000 | 3.14% |
| Catalent Inc. |
Closed
720,000
|
$31,219,200,000 | |
| Exact Sciences Corp. |
16.00%
420,000
|
$31,071,600,000 | 3.06% |
| Blueprint Medicines Corp |
47.36%
326,378
|
$30,105,107,000 | 2.97% |
| Pliant Therapeutics, Inc. |
7.23%
1,577,108
|
$28,561,426,000 | 2.82% |
| Denali Therapeutics Inc |
No change
1,300,000
|
$27,898,000,000 | 2.75% |
| Maxcyte Inc |
Closed
4,715,000
|
$21,641,850,000 | |
| 4d Molecular Therapeutics In |
3.38%
1,033,811
|
$20,945,011,000 | 2.07% |
| Tenaya Therapeutics Inc |
No change
6,381,377
|
$20,675,661,000 | 2.04% |
| Beam Therapeutics Inc. |
7.37%
528,000
|
$14,372,160,000 | 1.42% |
| AbCellera Biologics Inc. |
6.34%
2,360,129
|
$13,476,337,000 | 1.33% |
| Tango Therapeutics Inc |
18.83%
1,188,349
|
$11,764,655,000 | 1.16% |
| Century Therapeutics Inc |
No change
3,206,380
|
$10,645,182,000 | 1.05% |
| Avidity Biosciences, Inc. |
38.32%
1,175,750
|
$10,640,538,000 | 1.05% |
| Neurogene Inc |
Opened
524,616
|
$10,167,058,000 | 1.00% |
| Pacific Biosciences Calif In |
Opened
1,035,859
|
$10,161,777,000 | 1.00% |
| Twist Bioscience Corp |
Closed
450,000
|
$9,207,000,000 | |
| Genedx Holdings Corp |
No change
3,095,511
|
$8,512,655,000 | 0.84% |
| Fate Therapeutics Inc |
No change
2,050,000
|
$7,667,000,000 | 0.76% |
| Codexis Inc. |
Opened
2,000,000
|
$6,100,000,000 | 0.60% |
| 2seventy Bio Inc |
41.57%
1,182,623
|
$5,049,800,000 | 0.50% |
| Incyte Corp. |
Closed
77,500
|
$4,824,375,000 | |
| Sana Biotechnology Inc |
Closed
750,000
|
$4,470,000,000 | |
| Sage Therapeutics Inc |
Closed
90,000
|
$4,231,800,000 | |
| Absci Corporation |
28.87%
973,260
|
$4,087,692,000 | 0.40% |
| Prime Medicine Inc |
No change
367,175
|
$3,253,171,000 | 0.32% |
| Syndax Pharmaceuticals Inc |
Opened
150,000
|
$3,241,500,000 | 0.32% |
| Monte Rosa Therapeutics Inc |
No change
510,882
|
$2,886,483,000 | 0.28% |
| Standard BioTools Inc |
No change
1,200,000
|
$2,652,000,000 | 0.26% |
| Exscientia Plc |
No change
213,900
|
$1,371,099,000 | 0.14% |
| Lianbio |
No change
206,415
|
$922,675,000 | 0.09% |
| Mirati Therapeutics Inc |
Closed
23,814
|
$860,400,000 | |
| Singular Genomics Systems In |
1.62%
1,323,885
|
$609,119,000 | 0.06% |
| Kronos Bio, Inc. |
No change
123,839
|
$154,799,000 | 0.02% |
| Scilex Holding Co |
Closed
23,512
|
$130,962,000 | |
| No transactions found | |||
| Showing first 500 out of 45 holdings | |||